- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01754727
Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice (IDEA)
17 de enero de 2017 actualizado por: AbbVie (prior sponsor, Abbott)
The purpose of this study was to assess the proportion of AS patients achieving treatment response to adalimumab therapy.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
This post-marketing observational study (PMOS) was performed in a multi-country, multi-center, single-arm format.
Data were collected prospectively and retrospectively.
Adult patients with diagnosis of AS who were assigned for treatment with adalimumab (Humira®) were eligible for participation.
Each patient included in this study was to be observed during his/her adalimumab treatment for a maximum of 12 month period.
During this period four follow-up visits were planned for observation of the patient and documentation of data.
Ideally, these visits should have been performed approximately 3 (V1), 6 (V2), 9 (V3) and 12 (V4) months after the baseline visit (V0).
Tipo de estudio
De observación
Inscripción (Actual)
452
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra de probabilidad
Población de estudio
Study population consisted of participants with ankylosing spondylitis (AS) who were treated with adalimumab as per locally approved label and prescription guidelines.
The decision to be treated with adalimumab had to be independent from study inclusion.
Descripción
Inclusion Criteria:
- Had ankylosing spondylitis (AS) and was eligible to start and/or continue adalimumab therapy according to the local product label and prescription guidelines,
- Had been started on adalimumab therapy no more than one (1) month prior to the study enrollment
- Had negative result of tuberculosis (TB) screening test or was receiving tuberculosis prophylaxis as per local guidelines
- Provided written Authorization to the investigator to use and/or disclose personal and/or health data, or Informed Consent if requested by the Local Regulations
Exclusion Criteria:
- Had contraindications for the treatment with adalimumab
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Perspectivas temporales: Futuro
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Participants with Ankylosing Spondylitis (AS)
Participants with ankylosing spondylitis treated with adalimumab in routine clinical practice.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 at Month 12
Periodo de tiempo: Month 0 (baseline) and Month 12
|
The BASDAI score was determined using a simple, self-reported questionnaire that consists of 6 questions on disease activity.
Each question is scored from 0 to 10 (0 = no symptoms, 10 = very severe symptoms).
The BASDAI 50 score captures patients with 50% reduction in the BASDAI score compared to baseline as observed.
|
Month 0 (baseline) and Month 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Participants Achieving BASDAI 50
Periodo de tiempo: Month 3, Month 6 and Month 9
|
The BASDAI score was determined using a simple, self-reported questionnaire that consists of 6 questions on disease activity.
Each question is scored from 0 to 10 (0 = no symptoms, 10 = very severe symptoms).
The BASDAI 50 score captures patients with 50% reduction in the BASDAI score compared to baseline.
|
Month 3, Month 6 and Month 9
|
Percentage of Participants Achieving At Least 2.0 Score Decrease in Ankylosing Spondylitis Disease Activity (ASDAS) Score From Baseline
Periodo de tiempo: Month 3, Month 6, Month 9 and Month 12
|
The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.
The questionnaire covers disease activity, back pain, and peripheral pain/swelling assessed on a visual analogue scale (from 0 (normal) to 10 (extreme pain or disability) cm) and duration of morning stiffness on a numerical rating scale (from 0 to 10, with 0 being none and 10 representing a duration of 2 hours or longer).
The laboratory parameter is a measurement of C-reactive protein (mg/L) (CRP) or erythrocyte sedimentation rate (mm/h) (ESR).
Data from five variables (disease activity, back pain, duration of morning stiffness, peripheral pain/swelling, and either CRP or ESR values) are combined to yield a score ranging from 0 to no defined upper limit.
Higher scores indicate higher disease activity.
Clinically important improvement is defined as a change >= 1.1 units, and major improvement is defined as a change >= 2.0 units.
|
Month 3, Month 6, Month 9 and Month 12
|
Mean Change in the Number of Hospital Inpatient Days
Periodo de tiempo: 12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Difference in the number of hospital inpatient days during 12 months of adalimumab therapy and 12 months preceding the introduction of adalimumab therapy.
|
12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Mean Change in the Number of Hospitalizations
Periodo de tiempo: 12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Difference in the number of hospitalizations during 12 months of adalimumab therapy and 12 months preceding the introduction of adalimumab therapy.
|
12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Mean Change in the Number of Sick Leave Days
Periodo de tiempo: 12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Difference in the number of sick leave days during 12 months of adalimumab therapy and 12 months preceding the introduction of adalimumab therapy (in employed subjects only)
|
12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Mean Change in the Number of Sick Leaves
Periodo de tiempo: 12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Difference in the number of sick leaves during 12 months of adalimumab therapy and 12 months preceding the introduction of adalimumab therapy (in employed subjects only).
|
12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Mean Change in the Number of Outpatient Visits to Each Kind of Health Care Provider
Periodo de tiempo: 12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Difference in the number of outpatient visits to each kind of health care provider which includes general practitioner, rheumatologist, other specialists (ophthalmologist, gastroenterologist, dermatologist, physiatrist), physiotherapist and rheumatology nurse, during 12 months of adalimumab therapy and 12 months preceding the introduction of adalimumab therapy.
|
12 months prior to month 0 (baseline) and 12 months prior to month 12
|
Mean Change From Baseline in BASDAI Score
Periodo de tiempo: Month 3, Month 6, Month 9, Month 12 and Month 12 Last Observation Carried Forward (LOCF)
|
The BASDAI score was determined using a simple, self-reported questionnaire that consists of 6 questions on disease activity.
Each question is scored from 0 to 10 (0 = no symptoms, 10 = very severe symptoms).
|
Month 3, Month 6, Month 9, Month 12 and Month 12 Last Observation Carried Forward (LOCF)
|
Mean Change From Baseline in Ankylosing Spondylitis Disease Activity (ASDAS) Score
Periodo de tiempo: Month 3, Month 6, Month 9 and Month 12
|
The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.
The questionnaire covers disease activity, back pain, and peripheral pain/swelling assessed on a visual analogue scale (from 0 (normal) to 10 (extreme pain or disability) cm) and duration of morning stiffness on a numerical rating scale (from 0 to 10, with 0 being none and 10 representing a duration of 2 hours or longer).
The laboratory parameter is a measurement of C-reactive protein (mg/L) (CRP) or erythrocyte sedimentation rate (mm/h) (ESR).
Data from five variables (disease activity, back pain, duration of morning stiffness, peripheral pain/swelling, and either CRP or ESR values) are combined to yield a score ranging from 0 to no defined upper limit.
Higher scores indicate higher disease activity.
Remission is defined as ASDAS score <1.3.
Clinically important improvement is defined as a change >= 1.1 units, and major improvement is defined as a change >= 2.0 units.
|
Month 3, Month 6, Month 9 and Month 12
|
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score
Periodo de tiempo: Month 3, Month 6, Month 9 and Month 12
|
The BASFI is a numeric rating scale that uses self-reported patient evaluations to measure physical function impairment caused by AS.
It is a ten questions, each question was scored on a numerical rating scale that ranged from 0 (no functional impairment) to 10 (maximal impairment).
The mean of the ten questions was the total BASFI score.
A higher score indicates more severe impairment of functioning.
|
Month 3, Month 6, Month 9 and Month 12
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Director de estudio: Liliana Iosub, AbbVie
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Enlaces Útiles
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de diciembre de 2012
Finalización primaria (Actual)
1 de octubre de 2015
Finalización del estudio (Actual)
1 de octubre de 2015
Fechas de registro del estudio
Enviado por primera vez
19 de diciembre de 2012
Primero enviado que cumplió con los criterios de control de calidad
19 de diciembre de 2012
Publicado por primera vez (Estimar)
21 de diciembre de 2012
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
6 de marzo de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
17 de enero de 2017
Última verificación
1 de enero de 2017
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- P13-682
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .